Climb Bio, Inc. Common Stock (CLYM) Stock Price, Quote & AI Analysis
Live CLYM stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Climb Bio, Inc. Common Stock.
TradeVae provides AI-driven analysis and real-time market intelligence for Climb Bio, Inc. Common Stock (CLYM), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.
AI Analysis
Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.
Generating AI analysis...
Climb Bio, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.
Climb Bio, Inc. Common Stock Overview
Company information
Company Overview
Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.
Company Details
Technical Indicators
Key technical analysis metrics and signals
Loading technical indicators...
Valuation Metrics
Key valuation ratios and comparisons
Loading valuation metrics...
Climb Bio, Inc. Common Stock Earnings & Financial Statements
Earnings Calendar
Upcoming earnings dates and historical surprises
Loading earnings calendar...
Financial Statements
Income statements, balance sheets, and cash flow
Loading income statements...
Loading balance sheets...
Loading cash flow statements...